Key result
Radiotherapy for cancers of the breast, esophagus, lung, and lymph nodes can cause pathophysiological changes leading to short- and long-term radiation-induced cardiac toxicities.
Why the study?
Radiotherapy can cause short- and long-term cardiac toxicities, and understanding its effects on the heart is critical for optimizing cancer treatment and minimizing cardiac risk.
Does proton-based stereotactic arrhythmia radioablation improve organ-at-risk sparing compared to photon-based therapy in patients with refractory ventricular tachycardia?
Does proton-based stereotactic arrhythmia radioablation improve organ-at-risk sparing compared to photon-based therapy in patients with refractory ventricular tachycardia?
Proton stereotactic arrhythmia radioablation provides superior dosimetric sparing of critical organs-at-risk, including the heart, compared to photon therapy in patients with refractory ventricular tachycardia.
Chemotherapy, radiotherapy, and surgery constitute the three primary modalities employed in the treatment of patients with cancer. Radiotherapy, in particular, is a mainstay of treatment for patients with cancers of the breast, esophagus, lung, and lymph nodes. Prior studies have shown, however, that radiotherapy can impact the heart. Radiation exposure, in fact, can lead to pathophysiological changes that may result in short- and long-term radiation-induced cardiac toxicities. Such toxicities can cause substantial morbidity and may manifest clinically in the weeks to years after the completion of treatment. As a result, in both modern clinical practice and clinical trials, the heart has been recognized as an organ-at-risk, and radiotherapy treatment plans seek to minimize the dose that it receives. In this review, we focus on the impacts of radiotherapy on underlying cardiac risk factors, the pathophysiology of radiotherapy-induced cardiac changes, and the clinical impacts of radiotherapy on the heart. Due to the location of the heart, we focus primarily on patients who have received radiotherapy for cancers of the breast, esophagus, lung, and lymph nodes, and those who have received cardiac-directed therapy. We then elaborate on the ongoing attempts to further lower the doses delivered to the heart during therapeutic courses of radiation.
No takes yet. Share an insight, caveat, or question.
Hsieh et al. (2024) conducted a review in Cancers of the breast, esophagus, lung, and lymph nodes. Radiotherapy was evaluated. Radiotherapy for cancers of the breast, esophagus, lung, and lymph nodes can cause pathophysiological changes leading to short- and long-term radiation-induced cardiac toxicities.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: